Literature DB >> 30956575

Testing the ability of the nonalcoholic fatty liver disease fibrosis score to predict 1-year all-cause hospital admission.

Trace Heavener1, Ahmed Memon2, Shamyal Khan1, Sam Davis1, Lauren Sager3, Sharon DeMorrow4, Mark Jeffries5.   

Abstract

The nonalcoholic fatty liver disease fibrosis score (NFS) has been shown to be a cost-effective screening strategy in the primary care setting to determine when gastroenterology referral is needed, but NFS as a predictor of hospitalization within 1 year is uncertain. This retrospective observational cohort study involved 1803 patients with a diagnosis of nonalcoholic fatty liver disease or nonalcoholic steatohepatitis. The NFS was categorized into the following: low (less than -1.455), moderate (between -1.455 and 0.676), and high (>0.676). The average NFS score by hospital admission was -0.760, the average number of admissions was 1.81, and the median number of days to hospital admission was 135.8 days (45.5-363, 25th to 75th percentile). A univariate logistic regression model showed that NFS significantly predicted hospital admission (P = 0.007); however, a multivariate logistic regression model, after adjusting for hypertension and tobacco use, indicated that NFS was not significantly associated with hospital admission. Using the logistic regression model, hypertension predicted admission at low (P < 0.0001) and moderate (P = 0.0005) NFS. Using this same model, tobacco use also predicted admission at low (P < 0.0001) and moderate (P =  0.0002) NFS. The NFS should not be used to determine which patients are at increased risk of hospitalization.

Entities:  

Keywords:  Hospitalization; hypertension; nonalcoholic fatty liver disease fibrosis score; preventive care; tobacco use

Year:  2019        PMID: 30956575      PMCID: PMC6442901          DOI: 10.1080/08998280.2018.1543227

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  18 in total

1.  Getting more for their dollar: a comparison of the NHS with California's Kaiser Permanente.

Authors:  Richard G A Feachem; Neelam K Sekhri; Karen L White
Journal:  BMJ       Date:  2002-01-19

2.  Non-alcoholic fatty liver disease fibrosis score and FIB-4 scoring system could identify patients at risk of systemic complications.

Authors:  Yuka Takahashi; Masayuki Kurosaki; Nobuharu Tamaki; Yutaka Yasui; Takanori Hosokawa; Kaoru Tsuchiya; Hiroyuki Nakanishi; Jun Itakura; Namiki Izumi
Journal:  Hepatol Res       Date:  2014-10-15       Impact factor: 4.288

3.  The Framingham risk score and heart disease in nonalcoholic fatty liver disease.

Authors:  Sombat Treeprasertsuk; Scott Leverage; Leon A Adams; Keith D Lindor; Jennifer St Sauver; Paul Angulo
Journal:  Liver Int       Date:  2012-02-02       Impact factor: 5.828

4.  Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.

Authors:  Stuart McPherson; Stephen F Stewart; Elsbeth Henderson; Alastair D Burt; Christopher P Day
Journal:  Gut       Date:  2010-09       Impact factor: 23.059

5.  NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients.

Authors:  Sombat Treeprasertsuk; Einar Björnsson; Felicity Enders; Sompongse Suwanwalaikorn; Keith D Lindor
Journal:  World J Gastroenterol       Date:  2013-02-28       Impact factor: 5.742

6.  The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.

Authors:  Paul Angulo; Jason M Hui; Giulio Marchesini; Ellisabetta Bugianesi; Jacob George; Geoffrey C Farrell; Felicity Enders; Sushma Saksena; Alastair D Burt; John P Bida; Keith Lindor; Schuyler O Sanderson; Marco Lenzi; Leon A Adams; James Kench; Terry M Therneau; Christopher P Day
Journal:  Hepatology       Date:  2007-04       Impact factor: 17.425

Review 7.  Reducing hospital readmission rates: current strategies and future directions.

Authors:  Sunil Kripalani; Cecelia N Theobald; Beth Anctil; Eduard E Vasilevskis
Journal:  Annu Rev Med       Date:  2013-10-21       Impact factor: 13.739

8.  Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States.

Authors:  Donghee Kim; W Ray Kim; Hwa Jung Kim; Terry M Therneau
Journal:  Hepatology       Date:  2013-01-25       Impact factor: 17.425

9.  Non-alcoholic fatty liver disease (NAFLD) fibrosis score predicts 6.6-year overall mortality of Chinese patients with NAFLD.

Authors:  Yun-Hao Xun; Jian-Chun Guo; Guo-Qiang Lou; Yan-Ming Jiang; Zhen-Jie Zhuang; Meng-Fei Zhu; Yan Luo; Xiao-Jie Ma; Jing Liu; Dong-Xue Bian; Jun-Ping Shi
Journal:  Clin Exp Pharmacol Physiol       Date:  2014-09       Impact factor: 2.557

10.  Association between noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver disease.

Authors:  Giorgio Sesti; Teresa Vanessa Fiorentino; Franco Arturi; Maria Perticone; Angela Sciacqua; Francesco Perticone
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.